160 related articles for article (PubMed ID: 20443847)
1. The FDA regulatory process for drug and genetic diagnostic test approvals.
Bristow MR; Hiatt WR
Clin Transl Sci; 2008 Dec; 1(3):188-9. PubMed ID: 20443847
[No Abstract] [Full Text] [Related]
2. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
3. FDA halts 23andMe genetic tests.
Park A
Time; 2013 Dec; 182(24):18. PubMed ID: 24640794
[No Abstract] [Full Text] [Related]
4. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
5. 23andMe, the Food and Drug Administration, and the future of genetic testing.
Zettler PJ; Sherkow JS; Greely HT
JAMA Intern Med; 2014 Apr; 174(4):493-4. PubMed ID: 24535082
[No Abstract] [Full Text] [Related]
6. FDA Approves Direct-to-Consumer Cancer Genomics.
Eissenberg JC
Mo Med; 2018; 115(2):126. PubMed ID: 30228700
[No Abstract] [Full Text] [Related]
7. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
8. 23andme obtains permission to market Bloom syndrome test.
Am J Med Genet A; 2015 Jun; 167(6):viii-ix. PubMed ID: 26017705
[No Abstract] [Full Text] [Related]
9. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
10. In search of a coherent framework: options for FDA oversight of genetic tests.
Javitt GH
Food Drug Law J; 2007; 62(4):617-52. PubMed ID: 18557224
[No Abstract] [Full Text] [Related]
11. FDA: Gene tests need premarket approval.
Kuehn BM
JAMA; 2010 Jul; 304(2):145. PubMed ID: 20628120
[No Abstract] [Full Text] [Related]
12. Regulatory watch: FDA new drug approvals in Q2 2018.
Urquhart L
Nat Rev Drug Discov; 2018 Jul; 17(8):536-537. PubMed ID: 30057412
[No Abstract] [Full Text] [Related]
13. Theranos Experience Exposes Weaknesses in FDA Regulatory Discretion.
Jotwani R; Boumil M; Salem D; Wetterhahn M; Beninger P
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):433-438. PubMed ID: 28741304
[No Abstract] [Full Text] [Related]
14. How will the FDA impact the laboratory developed test?
Davis J; Wentz J
Clin Lab Sci; 2007; 20(3):130-1. PubMed ID: 17691668
[No Abstract] [Full Text] [Related]
15. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
16. FDA drug approvals from 1994 to 1995.
Wynn RL
Gen Dent; 1996; 44(2):114, 116, 118. PubMed ID: 8690259
[No Abstract] [Full Text] [Related]
17. FDA drug approvals in 1993-94.
Wynn RL
Gen Dent; 1995; 43(1):12, 14. PubMed ID: 7758913
[No Abstract] [Full Text] [Related]
18. The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics.
Goodsaid FM
Clin Transl Sci; 2019 Sep; 12(5):431-439. PubMed ID: 31162800
[TBL] [Abstract][Full Text] [Related]
19. FDA new drug approvals in 2006.
Wynn RL
Gen Dent; 2007; 55(4):275-9. PubMed ID: 17682633
[No Abstract] [Full Text] [Related]
20. FDA new drug approvals in 2004.
Wynn RL
Gen Dent; 2005; 53(4):246-8. PubMed ID: 16158789
[No Abstract] [Full Text] [Related]
[Next] [New Search]
